Extremely slow methotrexate elimination in a patient with t(9;22) positive acute lymphoblastic leukemia treated with imatinib.

Authors :: Van Hest RM
Schnog JB
Van't Veer MB
Cornelissen JJ
Source :: American journal of hematology [Am J Hematol] 2008 Sep; Vol. 83 (9), pp. 757-8.
Publication Year :: 2008

Subjects :: Antimetabolites, Antineoplastic administration & dosage
Antimetabolites, Antineoplastic analysis
Benzamides
Chromosomes, Human, Pair 22 ultrastructure
Chromosomes, Human, Pair 9 ultrastructure
Cytarabine administration & dosage
Drug Interactions
Edema chemically induced
Edema drug therapy
Etoposide administration & dosage
Female
Humans
Imatinib Mesylate
Leucovorin therapeutic use
Methotrexate administration & dosage
Methotrexate analysis
Middle Aged
Piperazines administration & dosage
Piperazines adverse effects
Pleural Effusion, Malignant chemically induced
Pleural Effusion, Malignant chemistry
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma metabolism
Pyrimidines administration & dosage
Pyrimidines adverse effects
Sodium Potassium Chloride Symporter Inhibitors therapeutic use
Translocation, Genetic
Antimetabolites, Antineoplastic pharmacokinetics
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Methotrexate pharmacokinetics
Piperazines pharmacology
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma drug therapy
Pyrimidines pharmacology

Full Text Access

Tools